EAN 2025: Efgartigimod Approved in EU for CIDP
At EAN 2025, Professor Giuseppe Lauria presented results from the ADHERE trial, showing that efgartigimod is effective in treating CIDP with a response rate of around 60%. Recently, efgartigimod was approved in the EU for the treatment of CIDP. Efgartigimod is administered subcutaneously, which reduces the need for hospital-based treatment and minimizes side effects.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in